New drug cocktail aims to boost kidney cancer surgery success
NCT ID NCT07627464
First seen Jun 10, 2026
Summary
This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal is to see if the combo helps preserve kidney function and reduces complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huadong Hospital Affiliated to Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Provincial Cancer Hospital
Changsha, China
Contact
-
Jilin Provincial Cancer Hospital
Changchun, China
Contact
-
Liaoning Provincial Cancer Hospital
Shenyang, China
Contact
-
Nanjing Drum Tower Hospital
Nanjing, China
Contact
-
Peking University Third Hospital
Beijing, China
Contact
-
Shanxi Province Cancer Hospital
Taiyuan, China
Contact
-
The Affiliated Hospital of Qingdao University
Qingdao, China
Contact
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Contact
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Contact
-
Yunnan Provincial Cancer Hospital
Kunming, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib hydrochloride and benmelstobart
What this could lead to
If successful, this approach could improve kidney function preservation and surgical outcomes for patients with localized kidney cancer, potentially reducing the need for more extensive surgery.
What could go wrong
This is an early Phase 2 trial with only 144 participants, so results may not apply to all patients. The combination therapy may cause side effects and may not improve outcomes compared to surgery alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.